Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance
about
Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study.miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis.Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.Blueberry as a Potential Radiosensitizer for Treating Cervical Cancer.Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
P2860
Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@ast
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@en
type
label
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@ast
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@en
prefLabel
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@ast
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@en
P2860
P50
P1476
Bcl-2 confers survival in cisp ...... endent toxicity and resistance
@en
P2093
Gina Leisching
P2860
P2888
P356
10.1186/S12967-015-0689-4
P577
2015-10-16T00:00:00Z
P5875
P6179
1018307474